UAMY Reiterates Expansion Plans, But Execution Risk Remains

What happened

United States Antimony Corp. (UAMY) used a company presentation to highlight expanded processing capacity, domestic mineral supply initiatives, and a potential antimony-copper-silver processing joint venture, echoing themes management has emphasized throughout 2026. These strategic ambitions are real—the company holds a five-year sole-source Defense Logistics Agency contract and a $27 million Defense Production Act award—but they have not yet translated into financial performance. Despite cumulative DLA orders of $57.3 million, only about $2.6 million of shipments were accepted and recognized by the end of Q2, and management cut FY2026 revenue guidance from $125 million to $60–75 million. The stock currently trades around $5.34, implying a market cap of roughly $794 million, which prices in a smooth ramp that has repeatedly slipped; Q2 gross margin collapsed to 7% from 27%, and inventory rose to $21.6 million without corresponding revenue. The presentation may reassure strategic buyers, but for equity investors the next quarter remains a prove-it period, with accepted DLA shipments, margin recovery above 15%, and inventory conversion as the key checkpoints.

Implication

The October presentation adds no new fundamental data and should not alter the cautious stance from the DeepValue report, which rates UAMY a POTENTIAL SELL with a trim level above $6.50. The company's balance sheet remains strong with $41.4 million in cash and no borrowings, providing a buffer, but that liquidity was built through heavy equity issuance and does not guarantee operating leverage. Key risks include further delays in DLA shipment acceptance, rising inventory, and the need for more capital before Thompson Falls proves stable output, all of which could pressure the stock toward the bear-case implied value of $4.00. Conversely, if Q3 reports show recognized government sales near the guided $9–10 million and gross margin rebounds above 15%, the thesis could improve, but the burden of proof is on management. Investors should wait for concrete evidence in the next quarterly report before adding positions, focusing on shipment acceptance, margin trends, and whether inventory declines rather than relying on presentation rhetoric.

Thesis delta

The expansion and JV commentary confirms UAMY's strategic positioning but does not alter the core thesis that the stock is overpriced relative to demonstrated execution. The DeepValue report's POTENTIAL SELL rating and $6.50 trim level remain appropriate; the company still needs to show accepted DLA shipments, margin recovery, and inventory monetization before a higher valuation is warranted. No shift is warranted based on this presentation; it is a reiteration of previously disclosed plans rather than new evidence of progress.